BioCryst Pharmaceuticals, Inc.
PLASMA KALLIKREIN INHIBITORS AND METHODS OF USE THEREOF IN OCULAR DISORDERS

Last updated:

Abstract:

This disclosure is generally in the field of ophthalmic therapies, and more particularly to the treatment of various ocular diseases and conditions by non-surgical administration to the eye of a subject of a drug composition described herein containing a plasma kallikrein inhibitor. Plasma kallikrein inhibitors include avoralstat. The compositions and methods include delivery of a plasma kallikrein inhibitor to the suprachoroidal space (SCS) of the eye.

Status:
Application
Type:

Utility

Filling date:

8 Apr 2020

Issue date:

26 May 2022